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ABSTRACT
Introduction: Medical device infections are
associated with significant morbidity and
mortality. These difficult-to-treat infections
often result in antibiotic failure and resistance.
Combination therapy is often required,
however, the most optimal combination is
unknown. We evaluated the in vitro activity
of daptomycin (DAP) or vancomycin (VAN)
alone and in combination with rifampin (RIF)
or clarithromycin (CLA) against strains of
Staphylococcus aureus and S. epidermidis grown
in biofilm on 3 prosthetic device materials.
Methods: One methicillin-resistant S. aureus
(MRSA R5266), one heteroresistant
vancomycin-intermediate S. aureus (hVISA
R3640), and one methicillin-resistant S.
epidermidis (MRSE R461) strain was evaluated
in a CDC biofilm reactor with titanium,
Teflon, and steel coupons. Regimens
simulated included DAP 10 mg/kg/day, and
VAN 1 g q12h alone or in combination with
RIF 600 mg q24h or CLA 250 mg q12h.
Additional regimens including DAP 12 mg/kg/
day or VAN ± RIF 450 mg q12h were evaluated
against the hVISA strain.
Results: DAP ? RIF or VAN ? RIF demonstrated
enhanced activity against R3640 in embedded
biofilm (EB) cells in all materials versus DAP or
VAN alone (P B 0.040). Only DAP ? RIF
demonstrated sustained bactericidal activity
(C3.80 log10 CFU/cm
2 reduction from
baseline) against EB and planktonic cells of
R5266 and EB cells of R461 in all 3 materials. Of
interest, CLA did not appear to enhance DAP or
VAN killing activities, and the addition of RIF
prevented the emergence of resistance to DAP
or VAN in all organisms.
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Conclusion: Using an in vitro bacterial biofilm
model containing three common prosthetic
device materials, DAP ? RIF and VAN ? RIF
were the most effective regimens. DAP ? RIF
displayed the greatest activity and represents a
promising combination to evaluate for
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INTRODUCTION
Despite advances in bioengineering and the
widespread use of antibiotic prophylaxis,
medical implant infections represent a
significant source of morbidity in the United
States [1]. Two of the most common causative
agents of perioperative infections are
Staphylococcus aureus and coagulase-negative
staphylococci (CoNS), in particular S.
epidermidis [1]. Both species are frequent
commensal organisms of the human skin, and
insertion of medical implants through the skin
may result in the colonization of these devices.
Attached to the surface of the implant, bacteria
aggregate in a hydrated polymeric matrix
forming sessile communities of biofilm, well
protected against hostile conditions of the
environment, including antimicrobial
exposure [2, 3].
Staphylococci spp., especially multidrug-
resistant Staphylococci spp. organized in
biofilm, represent a significant challenge for
clinicians making it difficult or impossible to
treat with antimicrobial agents, and
detachment from the device may result in
systemic infections [4]. Daptomycin (DAP) is a
potent lipopeptide that has demonstrated rapid
and concentration-dependent bactericidal
activity against Staphylococci spp. [5]. Although
DAP is known to rapidly penetrate the matrix of
biofilm, little is known about the
pharmacodynamic activity of DAP in biofilm-
associated infections to explain the observed
reduced bactericidal activity [6]. Various in vitro
models have investigated the activity of DAP
against staphylococci biofilms, but most of
them have specific limitations. The majority of
these models evaluate drug activity under static
conditions using a unique type of material, or
they do not allow for the investigation of the
structure of the biofilm secondary to drug
exposure [7–10]. We previously modified an
existing commercially available biofilm model
for pharmacokinetic/pharmacodynamic (PK/
PD) evaluation of the in vitro activity of
antimicrobials against mature biofilm of
Staphylococci spp. under conditions mimicking
human pharmacokinetics [11]. Using this
model, we have demonstrated moderate
activity of high-dose DAP alone against
biofilm embedded methicillin-sensitive S.
aureus (MSSA) and methicillin-resistant S.
aureus (MRSA) isolates on polycarbonate
coupons. Combining DAP with RIF or CLA
appeared promising as a significant increase in
killing activity was noted against DAP-
susceptible MRSA or MSSA, respectively [11].
Macrolides like azithromycin and CLA have
been shown to decrease the production of
polysaccharide glycocalyx by bacteria and
have demonstrated synergy with other
antibiotics against biofilm-embedded
organisms [11, 12]. Even in strains with
diminished susceptibility, CLA has been
shown to eradicate the polysaccharide
glycocalyx matrix surrounding MRSA and S.
epidermidis bacterial colonies, subsequently
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decreasing biofilm formation and increasing
drug penetration [11, 13, 14].
The objective of the present study was to
quantify the ability of S. aureus and S.
epidermidis with varying antibiotic
susceptibility profiles (MRSA, heteroresistant
vancomycin-intermediate S. aureus [hVISA],
methicillin-resistant S. epidermidis [MRSE]) to
form biofilms and to evaluate the activity of
DAP alone or in combination with RIF and CLA
against cells embedded in biofilm on titanium
(TT), Teflon (TE) and steel (ST) coupons.
MATERIALS AND METHODS
Bacterial Strains
Two MRSA (R5266 and R3640), including 1
hVISA (R3640) confirmed by population
analysis, and 1 MRSE (R461) were selected
from the Anti-Infective Research Laboratory
collection to be evaluated.
Antimicrobials
Daptomycin analytical powder was provided by
the manufacturer (Cubist Pharmaceuticals, Inc.,
Lexington, MA, USA). Stock solutions were
prepared according to manufacturer’s
recommendations. Vancomycin (VAN), CLA
and RIF were purchased form Sigma-Aldrich
(St. Louis, MO, USA). CLA and RIF were
reconstituted following Clinical Laboratory
Standards Institute (CLSI) guidelines using
methanol and prepared freshly prior to each
experiment [15].
Media
Tryptic Soy broth supplemented with 1%
glucose (gSTSB) and 1/10th gSTSB were used
for the 24- and 16-h conditioning phase,
respectively, to facilitate biofilm formation.
Mueller–Hinton broth (MHB II; Difco, Detroit,
MI, USA) supplemented with 25 or 50 mg/L
(SMHB II) of calcium for in vitro experiments
using VAN or DAP, respectively, and 12.5 mg/L
magnesium. Colony counts were determined
using Tryptic Soy Agar (TSA; Difco, Detroit, MI,
USA) plates.
Susceptibility Testing
Susceptibility testing of all antimicrobials to
determine minimum inhibitory concentrations
(MIC) and minimum bactericidal
concentrations (MBC) was performed in
duplicate by broth microdilution at*5 9 105
colony-forming unit (CFU)/mL in MHB II or
SMHB II according to Clinical and CLSI
guidelines [15]. Biofilm MICs (MBIC) of all
antimicrobials were performed using the pin-
lid method as previously described [16]. Drug-
containing plates at threefold the organism
MIC were used to screen for changes in
susceptibility.
In Vitro PK/PD Model
Isolates were grown on TSA plates incubated at
37 C for 24 h and then suspended in normal
saline to reach a concentration equivalent to a
0.5 McFarland. The in vitro model consisted of a
previously described CDC biofilm reactor (CBR)
model (BioSurfaces Technologies, Bozeman,
MT, USA), which we modified to run PK/PD,
simulating human PK to evaluate the in vitro
activity of antimicrobials [11, 17, 18]. Briefly, a
40-h biofilm conditioning phase was performed
prior to drug therapy initiation and consisted of
a 24 h incubation at 37 C in 1% gSTSB
inoculated with the specified organism,
followed by 16 h of a continuous flow with
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1/10th gSTSB performed with peristaltic pumps
(Masterflex; Cole-Parmer Instrument
Company, Chicago, IL, USA). Upon
completion of conditioning and continuous
flow phases (T0), MHB II (SMHB II for DAP-
containing regimens) was used as media for the
drug therapy phase, and boluses of antibiotics
were injected into the reactor. Each CBR model
held 8 rods with 3 coupons each, allowing for 3
different biomaterials (TT, TE and ST) in each
rod. The coupons had a surface area of 3.17 cm2.
The CBR was placed in a 37 C incubator room
throughout the procedure. Fresh media were
continuously supplied and removed from the
compartment along with the drug via a
peristaltic pump set to simulate the antibiotic
half-lives. Free drug concentrations were used,
and simulated regimens for each strain
included: DAP10 mg/kg/day [target free drug
peak concentration (fCmax) 11.3 mg/L; free area
under the concentration–time curve from 0 to
24 h (fAUC0–24) 83.1 mg h/L; average half-life,
8 h; protein binding, 92%] [19], alone or in
combination with CLA 250 mg q12h (fCmax
1 mg/L; average half-life 3.5 h; protein binding
50%) [20], or RIF 600 mg q24h (fCmax 3.5 mg/L;
average half-life 3 h; protein binding 80%) [21–
23], and VAN 2 g q12h (fCmax 30 mg/L; average
half-life 6 h; protein binding 50%) [24, 25]
alone or in combination with CLA 250 mg
q12h or RIF 600 mg q24h. For the hVISA
strain, 3 additional regimens were also
incorporated: DAP 12 (DAP12) mg/kg/day
(fCmax 14.7 mg/L; fAUC0–24 102.2 mg h/L),
alone and in combination with RIF 450 mg
q12h (fCmax 2.9 mg/L) [26, 27], and VAN 2 g
q12h in combination with RIF 450 mg q12h. A
growth control was run in the absence of drug
(simulated half-life 8 h), and each regimen was
run in duplicate to ensure reproducibility.
Pharmacodynamic Analysis
One rod was aseptically removed from each
model at 0, 4, 8, 24, 48 and 72 h. Each coupon
was rinsed with sterile normal saline to remove
excess planktonic cells (P). Biofilm-embedded
bacteria (BEB) were recovered from the
coupons by 3 alternating 60-s cycles of
vortexing and sonication at 20 Hz (Bransonic
12; Branson Ultrasonic Corporation, Danbury,
CT, USA) and a final 60 s of vortexing as
previously described [11]. Recovered biofilm
cells were serially diluted in normal saline and
spiral plated with an automatic spiral plater
(WASP; DW Scientific, West Yorkshire, UK)
onto TSA to allow enumeration of viable
colonies. Biofilm-embedded cell
concentrations (mean and standard deviation
in CFU/cm2) were then computed for each
coupon. Colonies were read using protocol
reader (ProtoCOL; Microbiology International,
Frederick, MD, USA). These methods were
reliable to a lower limit of detection of 1-
log10 CFU/cm
2. The total reduction in log10
CFU/cm2 over 72 h was determined by plotting
time-kill curves based on the number of viable
organisms over the time period. Bactericidal
activity (99.9% kill) was defined as a C3-log10
CFU/cm2 reduction in colony count from
initial inoculum. Bacteriostatic activity was
defined as a\3-log10 CFU/cm
2 reduction in
colony count from the initial inoculum, and
inactivity was defined as no observed reduction
in initial inocula. The time to achieve a 99.9%
bacterial load reduction was determined by
linear regression (if r2 C 0.95) or visual
inspection. Therapeutic enhancement of
combination regimens was defined as C2-
log10 CFU/cm
2 reduction over the most active
single agent.
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Pharmacokinetic Analysis
Pharmacokinetic samples were obtained,
through the injection port of each model at
the same time points as PD analysis for
verification of target antibiotic
concentrations. All samples were stored at
-70 C until ready for analysis. VAN
concentrations were measured by fluorescence
polarization immunoassay (TDx; Abbott
Diagnostics). Interday coefficients of variance
(CV%) were less than 9% for low, medium and
high standards (7, 35 and 75 mg/L),
respectively. Concentrations of RIF were
determined by bioassay utilizing Kocuria
rhizophila (formerly Micrococcus luteus) ATCC
9341 as previously described [28]. Briefly, -
inch holes were punched in agar plates
(antibiotic medium 11) pre-swabbed with a
0.5 McFarland suspension of the test organism
and filled with 50 lL of standards or samples.
This assay demonstrated a CV% of less than 5%
for 2.5, 5, and 10 mg/L standards. CLA
concentrations were measured by bioassay
using Bacillus subtilis ATCC 6631 and
antibiotic medium 11 following the same
procedure. Each standard was tested in
duplicate. Intraday CV% were less than 7%
for 1, 2, and 5 mg/L. Plates were incubated for
18–24 h at 37 C at which time the zone sizes
were measured using a protocol reader
(Protocol; Microbiology International,
Frederick, MD, USA). Concentrations of DAP
were validated utilizing high-performance
liquid chromatography (HPLC) [29–31].
Briefly, 100 lL of samples were processed with
200 lL of 0.1% formic acid in methanol. After
centrifugation, supernatant was removed and
transferred to an auto-sampler vial for
injection. An isocratic buffer consisting of
35% acetonitrile and 65% of ammonium
phosphate buffer (0.5%) was run at a flow
rate of 1.0 mL/min. A Nova-Pak C18 column
(3.9 9 150 mm; Waters Corp., Milford, MA,
USA) was used for separation. Standards were
prepared over the range of 3.75–50 mg/L, and
interday CV% were less than 11% for low,
medium and high standards, with a standard
curve r2 of 0.99.
The half-life (t1/2), areas under the curve
(AUC), and fCmax were determined by the
trapezoidal method utilizing PK Analyst
software (Version 1.10, MicroMath Scientific
Software, Salt Lake City, UT, USA).
Resistance
Susceptibility testing of colonies recovered at 48
and 72 h was performed according to CLSI
M100-S21 guidelines to evaluate changes in
MIC values from baseline isolates. Similarly,
biofilm MICs were performed to evaluate any
changes in MBICs.
Biofilm Quantification
Capacity of organisms to form biofilm was
assessed by the crystal violet method as
previously described [32, 33]. Bacterial strains
were grown in 96-well polystyrene flat bottom
trays for 24 h using gSTSB, 2% NaCl and 50 mg/
L calcium. After incubation, the broth
containing free planktonic cells was drained,
washed with normal saline and each well was
stained with 2% crystal violet, rinsed with
deionized water and dried. Following drying,
33% (vol/vol) glacial acetic acid was added to re-
solubilize the dye and break down the biofilm
for reading. Adherent presence of biofilm was
measured at optical density (OD)570 using a
spectrophotometer. Control strains for low,
medium and high biofilm production in this
assay were ATCC 12228, 35556 and NRS 101,
respectively.
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Scanning Electron Microscopy (SEM)
Coupons from rods recovered at 0 and 72 h
were evaluated for presence and structure of
biofilm by SEM. After removal, coupons were
rinsed in normal saline to remove non-adherent
cells and immersed in a fixative solution
containing 2.5% glutaraldehyde and 2%
paraformaldehyde in 0.1 M sodium phosphate
buffer. Coupons were then dehydrated in a
graded ethanol series and carbon coated at 30 A
for 3 min utilizing a SeeVac Conductavac IV
sputter coater (Seevac Inc., Pittsburgh, PA,
USA). The coupons were imaged using a
Hitachi S570 SEM at 2,0009 magnification and
evaluated for the presence and characteristics of
biofilm.
Statistical Analysis
Changes in CFU/mL for planktonic and CFU/
cm2 for biofilm-embedded bacteria at 72 h were
compared by one-way analysis of variance
(ANOVA) with Tukey’s Post Hoc test. A P value
of B0.05 was considered significant. All
statistical analyses were performed using SPSS
Statistical Software (Release 20.0, SPSS Inc.,
Chicago, IL, USA).
Compliance with Ethics
This article does not involve any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
Organism susceptibilities are displayed in
Table 1. All three isolates were susceptible to
DAP (MICs and MBCs of 0.25–0.5 mg/L), VAN
(MIC 1 mg/L, MBC ranging from 1 to 4 mg/L)
and RIF (MIC\0.0625 mg/L, MBC = 0.5 mg/L).
In contrast, all strains were resistant to CLA
(MIC[32 mg/L). MBICs for all isolates against
were two- to four-fold higher than reported
MICs. Changes in organism susceptibilities post
model experiments are reported in Table 2.
All strains produced biofilm. MRSA 5266
biofilm production was similar to the low
biofilm control strain 12228, while hVISA 3640
produced 50% more than control strain 12228
and 40% more than MRSA 5266. The CoNS
strain (MRSA 461) produced the highest
amounts of biofilm with 75 and 50% higher
biofilm production compared to 5266 and 3640,
respectively, and quantification most
comparable to the medium producing control
strain 35556.
The in vitro PK/PD model activities of
antimicrobials are displayed in Table 2 and
Fig. 1. Table 3 summarizes the observed PK
parameters of simulated regimens.
Against MRSA 5266 and MRSE 461 (Fig. 1a,
b), only DAP combined with RIF demonstrated
therapeutic enhancement, even reaching
bactericidal activity and exceeding 4 log10
CFU/cm2 kill (range 4.13–4.38) when using TT,
TE and ST. Reduction in the colony counts from
baseline (T0) to 72 h were significantly greater
on TT and ST coupons from baseline (T0) to 72 h
(D0 to 72, P B 0.032, P B 0.024, respectively)
than all other regimens (Fig. 1; Table 2). These
reductions were visible on SEM for MRSE 461
displaying fewer cells on TE coupons after
therapy with DAP and RIF at 72 h (Fig. 2a).
Although the combination of VAN ? RIF did
not display significant enhancement against
MRSA 5266 versus VAN alone, a[3 log10 CFU/
cm2 reduction (range 3.2–3.82) was noted for
this combination against MRSE 461 for TT, TE
and ST (P B 0.044). Regrowth at 48 h was
correlated with the emergence of resistance to
RIF (RIF MIC[32 mg/L) for DAP-containing
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regimen against MRSE 461. Resistance to RIF
was noted in the VAN ? RIF for 5266, however,
it was not correlated with regrowth. Against
platonic bacteria (PB) of both MRSE 461 and
MRSA 5266, DAP alone or combined with CLA
or RIF, and VAN displayed bactericidal activity,
however, only the combinations with RIF had
sustained activity over 72 h (data not shown).
The addition of CLA to VAN or DAP did not
improve killing activity compared to either
agent alone against PB (data not shown) or EB
of MRSA 5266.
Against hVISA 3640 (Fig. 1c), treatment with
DAP10 plus RIF 600 mg daily resulted in
therapeutic enhancement as did treatment of
VAN plus RIF 450 mg every 12 h in all materials
studied. DAP10 with RIF 600 mg once daily,
DAP12 plus RIF 450 mg every 12 h, and VAN
combined with RIF 600 mg once daily or
450 mg every 12 h demonstrated similar
killing in all materials studied and appeared
more efficacious over DAP10, DAP12, and VAN
with or without CLA. Although no regimen
achieved sustained bactericidal activity, DAP10
combined with RIF 600 mg was bactericidal at
48 h, and despite regrowth had the greatest
absolute reduction in colony count achieving
2.96 ± 0.52, 2.95 ± 0.04, and 2.82 ± 0.59 log10
CFU/cm2 for TT, TE and ST EB, and 6.64 ± 1.11
log10 CFU/mL for PB at 72 h, respectively.
Against TT coupon EB, DAP10 with RIF
600 mg daily, DAP12 with RIF 450 mg every
12 h and VAN with RIF 450 mg every 12 h
displayed significant killing over DAP with CLA
(P B 0.040). Against EB grown on TE, the three
regimens above demonstrated significantly
more reduction in colony counts than DAP12
monotherapy or DAP10 and VAN alone or in
combination with CLA (P B 0.016). Reductions
in viable EB densities from 0 to 72 h on TE and
ST coupons were significantly greater utilizing
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DAP12, DAP10 or VAN with or without CLA
(P B 0.028). VAN combined with RIF 600 mg
daily or 450 mg every 12 h displayed
significantly more killing in TE and ST EB than
DAP10 or DAP12 monotherapy and DAP or
VAN with CLA (P B 0.032) for PB and EB cells.
Regrowth with DAP10 monotherapy and DAP
with the addition of CLA was correlated to the
emergence of non-susceptibility at 72 h in EB
and PB (Table 2, DAP MIC = 2–8 mg/L, MBIC
8–16 mg/L), however, this was not the case with
DAP12 administered alone against EB. Increased
MIC to VAN was also observed at 72 h when
combined with CLA, with a change in MIC from
1 to 4 mg/L in TE EB.
DISCUSSION
Biofilm infections involving S. aureus and S.
epidermidis are associated with poor patient
Fig. 1 Activity of DAP and VAN alone and in combina-
tion against MRSA 5266 (a), MRSE 461 (b), and hVISA
3640 (c). Error bars denote SD. No signiﬁcant difference
was observed between kill curves obtained on TT, TE and
ST coupons, kill curves were combined into 1 graph for
clarity purposes. Solid line and ﬁlled circle GC, dash-dot line
and open circle DAP10, long dash line and inverse open
triangle DAP12, dotted line and open triangle DAP ? CLA,
short dash line and ﬁlled square DAP ? RIF, dash-dot line
and open square DAP ? RIF450, solid line and inverse ﬁlled
triangle VAN, solid line and opened diamond VAN ? CLA,
long dash and ﬁlled triangle VAN ? RIF, solid line and
opened triangle VAN ? RIF450. CLA clarithromycin, DAP
daptomycin, hVISA heteroresistant vancomycin-intermedi-
ate S. aureus, MRSA methicillin-resistant Staphylococcus
aureus, MRSE methicillin-resistant Staphylococcus epidermi-
dis, RIF rifampin, SD standard deviation, ST steel, TE
Teﬂon, TT titanium, VAN vancomycin
Infect Dis Ther (2015) 4:51–65 59
outcomes, increased hospitalization and
treatment costs. These infections are difficult
to eradicate due to increased organism
resistance and decreased antimicrobial
penetration. The 2008 UK MRSA prophylaxis
and treatment guidelines recommended
glycopeptides with or without adjunctive RIF
or sodium fusidate as parenteral therapy for
MRSA bone and joint infections [34]. Recently,
published Infectious Diseases Society of
America (IDSA) guidelines recommend VAN as
the preferred treatment for oxacillin-resistant
staphylococci prosthetic joint infections with
DAP or linezolid considered as alternative
therapy [27]. However, these guidelines point
out the research gap in alternatives to VAN for
management of MRSA and CoNS infection [35].
RIF has been previously used in osteomyelitis
and implant-related infection models and has
demonstrated activity against staphylococcal
biofilms [36–38]. Combination therapy with
RIF is recommended for RIF-susceptible joint
infections associated with biofilm formation,
however, monotherapy is discouraged due to
the high rate emergence of resistance. When
used in combination with DAP, increased
killing has been observed as well as a
reduction in the emergence of RIF or DAP
resistance [6, 27, 36, 39, 40]. However, the
guidelines fail to specify which antibiotics are
most advantageous to eradicate biofilm
infection in combination with RIF. Medical
devices are constructed from a variety of
biomaterials that include polycarbonate,
polyurethane, polystyrene, TE, ST and TT that
are widely used in osteoarticular prostheses,
fixation devices, pacemakers, prosthetic heart
valves and vascular grafts [41, 42]. Therefore, it
is important to explore the potential of
antibiotics used alone and in combination
against organisms that are frequently
associated with biofilms affecting these
materials.
In the current study, we evaluated the killing
activity of DAP and VAN against more difficult
to eradicate organisms grown on TT, TE and ST
materials. As the results indicate, the addition
of RIF to DAP and VAN expedited the
elimination of biofilm-embedded organisms.
The most potent activity was observed with
the combination of DAP and RIF in all three
organisms, followed by VAN plus RIF. The most
profound effect was seen against MRSA,
followed by hVISA and CoNS.
Table 3 Pharmacokinetic parameters of antimicrobials achieved in the PK/PD model
Drug, dosage fCmax (mg/L) (target value) Half-life (h) (target value) fAUC0–24 (mg h/L)
Daptomycin 10 mg/kg/day 10.82 ± 0.53 (11.3) 8.64 ± 0.1 (8) 123.1 ± 5.1
Daptomycin 12 mg/kg/day 14.22 ± 0.12 (14.7) 8.37 ± 0.46 (8) 158.3 ± 5.0
Vancomycin 2 g q12h 36.6 ± 1.8 (30) 6.19 ± 0.42 (6) 353.7 ± 4.1
Rifampin 600 mg daily 4.35 ± 0.24 (3.5) 2.24 ± 0.51 (3) 6.44 ± 0.02
Rifampin 450 mg q12h 4.06 ± 0.16 (2.9) 2.88 ± 0.12 (3) 18.07 ± 3.21
Clarithromycin 250 mg q12ha 1.51 ± 0.25 (1) 2.6 ± 1.4 (3.5) 4.2 ± 1.8
Results are expressed as means ± standard deviations
fCmax maximum free drug concentration, fAUC0–24 free area under the concentration–time curve from 0 to 24 h, PK/PD
pharmacokinetics/pharmacodynamics
a q12h, every 12 h
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Vancomycin has shown varied efficacy in
eradication of biofilm infections [43, 44].
Treatment outcomes may vary based on
biofilm production and limited VAN
penetration into the biofilm matrix [44]. High-
dose DAP alone or in combination with RIF has
been shown to have an increased effect and to
decrease the emergence of resistance in in vitro
and in vivo infection models [7, 11, 38]. We
have previously demonstrated sustained
bactericidal activity in in vitro models utilizing
high-dose DAP in combination with CLA
against biofilm-embedded MSSA [11]. DAP
with RIF displayed similar bacterial eradication
against a highly DAP-susceptible MRSA strain
against biofilm-embedded bacteria grown on
polycarbonate and also prevented the
emergence of resistance [11]. DAP non-
susceptibility has been associated with medical
device infections, specifically the monotherapy
dose of 6 mg/kg/day has been less effective in
eradicating adherent organisms [38, 39, 45]. In
the current experiment, increasing the dose to
12 mg/kg daily of DAP prevented emergence of
non-susceptible mutants in the hVISA strain,
therefore, increased dosages may be necessary
to eradicate organisms recovered from biofilm
and prevent further resistance from occurring.
The relatively high rate of emergence of
resistance to RIF is consistent with prior data
[11, 27, 28, 37]. The mechanism of resistance is
not well understood, however, rpoB gene
mutations and efflux mechanisms are thought
to contribute [46]. Development of RIF
resistance has previously been observed when
used as monotherapy in a catheter-lock model
[7]. DAP has been shown to reverse RIF
resistance in VAN-resistant Enterococcus
faecium. The mechanism is thought to be
through potentiating RIF binding to RNA
polymerase by increased permeabilization of
the outer membrane [46, 47]. In MRSA implant
infection models, a reduced incidence of RIF
resistance has been found in the presence of
DAP [48]. Of note, the addition of RIF prevented
development of non-susceptibility to DAP in all
isolates evaluated in our study. This finding is
consistent with other foreign-body infection
Fig. 2 MRSE 461 embedded bioﬁlm a Teﬂon coupon
prior to antibiotic exposure; b after 72 h of DAP ? RIF
exposure. SEM images are at 10009 magniﬁcation. DAP
daptomycin, MRSE methicillin-resistant Staphylococcus
epidermidis, RIF rifampin, SEM scanning electron
microscopy
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models, as well as in vivo in humans where DAP
mutants have been recovered with DAP
monotherapy, but the addition of RIF
prevented emergence of DAP and VAN
resistance in MRSA [36, 38]. Interestingly,
MRSE displayed a higher proclivity toward
development of RIF resistance compared to the
hVISA and MRSA isolates, although DAP non-
susceptibility was more common in the latter
two organisms.
The decreased killing potential of
combination therapy against CoNS may be
explained by the copious amount of biofilm
production as demonstrated by biofilm
quantification experiments. There was a trend
toward increased killing with the TE material in
the hVISA and MRSA organisms, but
interestingly not with the CoNS. This may be
explained by the amount of biofilm present as
well as the varying complexity of the biofilm
matrices associated with different biomaterials
[49]. One such study demonstrated a higher
biofilm forming potential with steel pipes
compared to those of polyethylene [49]. To see
if an increase in DAP and RIF exposure could
further improve killing, therefore, we
performed additional model experiments
utilizing DAP 12 mg/kg daily with RIF 450 mg
every 12 h (RIF dose as recommended by
Zimmerli et al.) against the hVISA 3640 strain
[26]. However, the increase in DAP and RIF
exposure did not appear to improve the overall
reduction in viable CFU/cm2 counts.
Previous studies including experiments that
we have conducted have shown enhanced
killing with the addition of CLA; the
mechanism is thought to be through
glycocalyx inhibition independent of
antimicrobial killing [11, 13, 14, 50]. Even in
strains with diminished susceptibility, CLA has
been shown to eradicate the polysaccharide
glycocalyx matrix surrounding MRSA and S.
epidermidis bacterial colonies, subsequently
decreasing biofilm formation and increasing
drug penetration [11, 13, 14]. However, these
past experiments primarily utilized time-kill
methodologies, a single type of material,
supratherapeutic CLA concentrations or
organisms with lower DAP MICs. This may
partially explain the lack of enhanced killing
observed with CLA in our present experiments.
Of interest, there is also evidence of CLA
promoting glycocalyx production in
Pseudomonas aeruginosa biofilms when
administered at sub-MIC concentrations [51].
Our model simulated bloodstream CLA PKs, and
therefore may not fully represent CLA activity
due to its high volume of distribution into
tissues. Further studies evaluating the role of
CLA as a potential agent for combination
therapy against biofilm-embedded organisms
are warranted.
Strengths of our study include examining
more difficult-to-treat organisms such as hVISA
and S. epidermidis with higher MICs to DAP than
those previously evaluated. Three separate
materials (TT, TE and TE) were run
simultaneously in the same model, which may
control for variables such as testing different
materials on different days. Our in vitro biofilm
reactor model is unique in that it has been
modified to simulate human PKs. Potential
limitations in this study included the use of a
limited amount of strains and, therefore, the
results may not be representative of all
staphylococci with varying susceptibility
patterns to VAN or DAP. In addition, the use
of different materials (TT, TE and ST) within the
same biofilm model may have influenced the
type of biofilm formation we observed and
therefore our results. Another potential
limitation was that the drug exposures were
carried out over 72 h. Longer antimicrobial
exposures may be needed to improve
62 Infect Dis Ther (2015) 4:51–65
penetration into biofilm, improve killing and
suppress the emergence of resistance.
In conclusion, the combination of DAP with
RIF demonstrated the most effective killing
against these three staphylococci isolates in a
model of embedded biofilm, followed by VAN in
combination with RIF. Further studies
evaluating different antimicrobial
combinations, additional staphylococci isolates
with varying susceptibility patterns and longer
durations of antibiotic exposure are warranted.
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